Fluidigm CORP: management transactions · United States · SEC (Form 4)

About Fluidigm CORP

FLUIDIGM CORP (ticker: FLDM) is a United States-based life science tools company that was listed on the NASDAQ market. The business was founded in 1999 in California and is headquartered in South San Francisco, placing it in one of the most important biotech clusters in the United States. Fluidigm built its reputation around enabling high-content biological analysis through microfluidic and single-cell technologies, and it has long served research customers that need precision, throughput, and reproducibility. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1162194/000116219422000021/fldm-20211231.htm?utm_source=openai)) From an operating perspective, the company’s core model has been the design, manufacture, and commercialization of instruments, consumables, reagents, and software for life science research and clinical research workflows. Historically, Fluidigm’s product portfolio was organized around two main areas: genomics and proteomics. In genomics, it developed microfluidic systems and integrated fluidic circuits (IFCs) used for molecular biology and targeted analysis workflows. In proteomics, it became widely known for CyTOF, its mass cytometry platform, which is designed for highly multiplexed single-cell profiling. This combination gave Fluidigm a differentiated niche in advanced research tools rather than broad-based commoditized laboratory equipment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1162194/000116219422000021/fldm-20211231.htm?utm_source=openai)) Its customer base has traditionally included academic and government laboratories, pharmaceutical and biotechnology companies, translational research centers, clinical research labs, and other organizations working in biology and medicine. The company’s competitive position has depended on technology depth more than scale: products such as Biomark, Access Array, CyTOF, Helios, CyTOF XT, Hyperion, Maxpar, and Pathsetter were built to address demanding applications such as immunophenotyping, oncology research, and high-dimensional cell analysis. Fluidigm’s markets are global, with commercial reach across North America, Europe, Asia-Pacific, and other international research hubs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1162194/000116219422000021/fldm-20211231.htm?utm_source=openai)) A major corporate milestone came in 2022, when Fluidigm completed a $250 million strategic capital infusion and changed its name to Standard BioTools Inc. That rebranding reflected a broader strategic reset toward becoming a more diversified life science tools company, while preserving the company’s technology heritage and core scientific franchises. For investors tracking FLDM as a historical ticker reference, it is important to note that the company’s public identity changed after April 2022, even though the underlying business assets and scientific platform remained recognizable. ([nasdaq.com](https://www.nasdaq.com/press-release/fluidigm-completes-%24250-million-strategic-capital-infusion-and-changes-name-to?utm_source=openai)) In short, FLUIDIGM CORP was a specialized, innovation-led life science instrumentation company with a strong legacy in microfluidics and mass cytometry. Its market appeal came from its exposure to high-value research workflows, its global customer base, and its role in enabling advanced biological discovery on the NASDAQ-listed U.S. market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1162194/000116219422000021/fldm-20211231.htm?utm_source=openai))